| Kevin Klembczyk, MD | |
|
1000 E Eager St, Baltimore, MD 21202-5533 | |
| (410) 522-9800 | |
| Not Available |
| Full Name | Kevin Klembczyk |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 7 Years |
| Location | 1000 E Eager St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063943983 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D0092712 (Maryland) | Secondary |
| 207R00000X | Internal Medicine | D0092712 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baltimore Medical System, Inc. | 5395653455 | 51 |
| Johns Hopkins University | 4981745098 | 571 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
| Entity Name | Baltimore Medical System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700882503 PECOS PAC ID: 5395653455 Enrollment ID: O20031121000651 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
| Entity Name | Johns Hopkins Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578598868 PECOS PAC ID: 8325943707 Enrollment ID: O20031220000065 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1902332133 PECOS PAC ID: 4981745098 Enrollment ID: O20170818000085 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Klembczyk, MD 1000 E Eager St, Baltimore, MD 21202-5533 Ph: () - | Kevin Klembczyk, MD 1000 E Eager St, Baltimore, MD 21202-5533 Ph: (410) 522-9800 |
News Archive
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors.
A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.
Millions of genetic variants have been discovered over the last 25 years, but interpreting the clinical impact of the differences in a person's genome remains a major bottleneck in genomic medicine. In a paper published in The New England Journal of Medicine on May 27, a consortium including investigators from Brigham and Women's Hospital and Partners HealthCare present ClinGen, a program to evaluate the clinical relevance of genetic variants for use in precision medicine and research.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
› Verified 4 days ago
Dr. Leonard Anang Sowah, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |